PLUR
Pluri Inc.
Price Chart
Latest Quote
$2.05
+0.03 (+1.49%)
Current Price
| Previous Close | $2.02 |
| Open | $2.10 |
| Day High | $2.10 |
| Day Low | $2.02 |
| Volume | 7,971 |
Stock Information
| Shares Outstanding | 10.79M |
| Total Debt | $33.63M |
| Cash Equivalents | $9.32M |
| Revenue | $1.08M |
| Net Income | $-25.54M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $22.12M |
| EPS (TTM) | $-2.90 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $51.70M |
| Sales | $1.08M |
| Income | $-25.54M |
| Book/sh | $-1.78 |
| Cash/sh | $0.86 |
| Employees | 127 |
Financial Ratios
| Quick Ratio | 0.29 |
| Current Ratio | 0.33 |
Returns & Margins
| ROA | -51.24% |
| Gross Margin | 43.00% |
| Operating Margin | -3913.77% |
Ownership
| Insider Ownership | 46.56% |
| Institutional Ownership | 12.55% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.08 |
| P/S | 20.50 |
| P/B | -1.15 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $2.30 |
| SMA50 | $2.91 |
| SMA200 | $3.49 |
| RSI | 26.32 |
| ATR | 0.1286 |
| Shares Float | 4.64M |
| Short Float | 0.90% |
| Short Ratio | 1.27 |
| Volatility | 0.62 |
| Rel Volume | 0.58 |
Performance History
| Week | -9.69% |
| Month | -21.15% |
| Quarter | -34.08% |
| 6 Months | -30.98% |
| YTD | -31.44% |
| Year | -52.44% |
| 3 Years | -71.53% |
| 5 Years | -94.10% |
| 10 Years | -98.10% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-22 | $2.05 | 7,971 |
| 2026-06-18 | $2.02 | 40,300 |
| 2026-06-17 | $2.25 | 8,600 |
| 2026-06-16 | $2.25 | 4,900 |
| 2026-06-15 | $2.33 | 5,500 |
| 2026-06-12 | $2.27 | 9,500 |
| 2026-06-11 | $2.25 | 10,900 |
| 2026-06-10 | $2.26 | 6,600 |
| 2026-06-09 | $2.38 | 6,600 |
| 2026-06-08 | $2.31 | 6,700 |
| 2026-06-05 | $2.36 | 7,200 |
| 2026-06-04 | $2.38 | 11,600 |
| 2026-06-03 | $2.36 | 3,100 |
| 2026-06-02 | $2.37 | 23,200 |
| 2026-06-01 | $2.41 | 49,700 |
| 2026-05-29 | $2.32 | 31,200 |
| 2026-05-28 | $2.35 | 9,200 |
| 2026-05-27 | $2.36 | 14,400 |
| 2026-05-26 | $2.31 | 14,200 |
| 2026-05-22 | $2.37 | 4,900 |
About Pluri Inc.
Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform. Its product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to coronavirus Disease (COVID-19), peripheral artery disease, intermittent claudication, and critical limb ischemia; PLX-R18, composed of fetal MSC like cells originating from the placenta for the treatment of hematopoietic complications of the H-ARS, and is in Phase I clinical trial to treat hematopoietic cell transplantation; and allogeneic MAIT cell therapy platform. The company also offers cell manufacturing services and cell-based coffee; and develops and commercializes cultivated meat products. It operates in the field of regenerative medicine, food tech, immunotherapy, CDMO, and AgTech. It has collaboration agreement with Bar-Ilan University to advance cancer immunotherapy for solid tumors. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
đ° Latest News
Pluri Inc. (PLUR): One of the Premier Lab-Grown Meat Stocks to Invest In
Insider Monkey âĸ 2026-05-30T15:46:21Z
Pluri Insider Ups Holding During Year
Simply Wall St. âĸ 2026-05-28T10:56:53Z
EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug
Benzinga âĸ 2026-05-01T20:00:52Z
Pluri: Fiscal Q2 Earnings Snapshot
Associated Press Finance âĸ 2026-02-12T22:12:15ZPluri showcases cell expansion platform as Resbiomed program advances
Proactive âĸ 2026-02-09T15:30:45Z
A US$3.4m Market Cap Boost Pleasing ToPluri Insiders
Simply Wall St. âĸ 2025-12-19T10:38:43Z
Pluri: Fiscal Q1 Earnings Snapshot
Associated Press Finance âĸ 2025-11-12T21:55:47ZPluri Subsidiary Coffeesai Partners with Mexicoâs INCAFECH to Advance Cell-Based Coffee Manufacturing
Insider Monkey âĸ 2025-10-24T12:07:22Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $682,000 | $4,000 | $9,000 | $0 |
| Cost Of Revenue | $682,000 | $4,000 | $9,000 | $0 |
| Total Revenue | $1,336,000 | $326,000 | $287,000 | $234,000 |
| Operating Revenue | $1,336,000 | $326,000 | $287,000 | $234,000 |
| Expenses | ||||
| Interest Expense | $873,000 | $866,000 | $843,000 | $887,000 |
| Total Expenses | $23,512,000 | $22,484,000 | $27,533,000 | $41,827,000 |
| Other Income Expense | $-1,350,000 | $274,000 | $-1,866,000 | $550,000 |
| Net Non Operating Interest Income Expense | $271,000 | $540,000 | $225,000 | $-331,000 |
| Interest Expense Non Operating | $873,000 | $866,000 | $843,000 | $887,000 |
| Operating Expense | $22,830,000 | $22,480,000 | $27,524,000 | $41,827,000 |
| General And Administrative Expense | $9,979,000 | $10,034,000 | $11,779,000 | $17,450,000 |
| Total Other Finance Cost | - | $-92,000 | $16,000 | $25,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-22,583,000 | $-20,888,000 | $-28,321,000 | $-41,242,000 |
| Net Interest Income | $271,000 | $540,000 | $225,000 | $-331,000 |
| Interest Income | $1,144,000 | $1,406,000 | $1,084,000 | $581,000 |
| Normalized Income | $-21,233,290 | $-21,162,000 | $-26,455,000 | $-41,792,000 |
| Net Income From Continuing And Discontinued Operation | $-22,583,000 | $-20,888,000 | $-28,321,000 | $-41,242,000 |
| Total Operating Income As Reported | $-22,176,000 | $-22,158,000 | $-27,246,000 | $-41,593,000 |
| Net Income Common Stockholders | $-22,583,000 | $-20,888,000 | $-28,321,000 | $-41,242,000 |
| Net Income | $-22,583,000 | $-20,888,000 | $-28,321,000 | $-41,242,000 |
| Net Income Including Noncontrolling Interests | $-23,250,000 | $-21,344,000 | $-28,887,000 | $-41,374,000 |
| Net Income Continuous Operations | $-23,250,000 | $-21,344,000 | $-28,887,000 | $-41,374,000 |
| Pretax Income | $-23,255,000 | $-21,344,000 | $-28,887,000 | $-41,374,000 |
| Operating Income | $-22,176,000 | $-22,158,000 | $-27,246,000 | $-41,593,000 |
| Gross Profit | $654,000 | $322,000 | $278,000 | $234,000 |
| Interest Income Non Operating | - | $1,406,000 | - | - |
| Per Share | ||||
| Diluted EPS | $-3.56 | $-3.99 | $-6.24 | $-10.24 |
| Basic EPS | $-3.56 | $-3.99 | $-6.24 | $-10.24 |
| Other | ||||
| Tax Effect Of Unusual Items | $-290 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-20,716,000 | $-20,499,000 | $-25,816,000 | $-39,984,000 |
| Total Unusual Items | $-1,350,000 | $274,000 | $-1,866,000 | $550,000 |
| Total Unusual Items Excluding Goodwill | $-1,350,000 | $274,000 | $-1,866,000 | $550,000 |
| Reconciled Depreciation | $316,000 | $253,000 | $362,000 | $1,053,000 |
| EBITDA (Bullshit earnings) | $-22,066,000 | $-20,225,000 | $-27,682,000 | $-39,434,000 |
| EBIT | $-22,382,000 | $-20,478,000 | $-28,044,000 | $-40,487,000 |
| Diluted Average Shares | $6,336,993 | $5,240,249 | $4,581,503 | $4,024,009 |
| Basic Average Shares | $6,336,993 | $5,240,249 | $4,581,503 | $4,024,009 |
| Diluted NI Availto Com Stockholders | $-22,583,000 | $-20,888,000 | $-28,321,000 | $-41,242,000 |
| Minority Interests | $667,000 | $456,000 | $566,000 | $132,000 |
| Tax Provision | $-5,000 | $0 | - | - |
| Gain On Sale Of Security | $-1,350,000 | $274,000 | $-1,866,000 | $550,000 |
| Research And Development | $12,851,000 | $12,446,000 | $15,745,000 | $24,377,000 |
| Selling General And Administration | $9,979,000 | $10,034,000 | $11,779,000 | $17,450,000 |
| Other Gand A | $9,979,000 | $10,034,000 | $11,779,000 | $17,450,000 |
Fetched: 2026-06-18
Balance Sheet (Annual)
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-12,771,000 | $96,000 | $13,355,000 | $30,039,000 |
| Total Assets | $38,683,000 | $39,527,000 | $50,797,000 | $68,065,000 |
| Total Non Current Assets | $16,588,000 | $8,420,000 | $9,388,000 | $10,318,000 |
| Other Non Current Assets | $1,326,000 | $704,000 | $628,000 | $648,000 |
| Goodwill And Other Intangible Assets | $5,929,000 | $0 | - | - |
| Other Intangible Assets | $2,793,000 | - | - | - |
| Current Assets | $22,095,000 | $31,107,000 | $41,409,000 | $57,747,000 |
| Hedging Assets Current | $103,000 | $8,000 | - | $0 |
| Restricted Cash | $422,000 | $254,000 | $269,000 | $1,007,000 |
| Prepaid Assets | $235,000 | $222,000 | $442,000 | $403,000 |
| Receivables | $722,000 | $638,000 | $527,000 | $1,321,000 |
| Other Receivables | $8,000 | $2,000 | $38,000 | $22,000 |
| Taxes Receivable | $290,000 | $135,000 | $129,000 | $344,000 |
| Accounts Receivable | $424,000 | $501,000 | $360,000 | $955,000 |
| Cash Cash Equivalents And Short Term Investments | $20,613,000 | $29,985,000 | $40,171,000 | $55,016,000 |
| Cash And Cash Equivalents | $5,895,000 | $6,783,000 | $5,360,000 | $9,772,000 |
| Non Current Prepaid Assets | - | - | - | $0 |
| Debt | ||||
| Net Debt | $21,394,000 | $17,244,000 | $18,170,000 | $11,906,000 |
| Total Debt | $34,050,000 | $29,612,000 | $29,905,000 | $28,802,000 |
| Long Term Debt And Capital Lease Obligation | $6,102,000 | $29,053,000 | $29,278,000 | $28,183,000 |
| Current Debt And Capital Lease Obligation | $27,948,000 | $559,000 | $627,000 | $619,000 |
| Current Debt | $27,289,000 | - | - | - |
| Other Current Borrowings | $27,289,000 | - | - | - |
| Long Term Debt | - | $24,027,000 | $23,530,000 | $21,678,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $39,548,000 | $34,112,000 | $35,497,000 | $35,879,000 |
| Total Non Current Liabilities Net Minority Interest | $7,220,000 | $29,658,000 | $29,876,000 | $29,050,000 |
| Non Current Deferred Liabilities | $415,000 | $0 | - | - |
| Non Current Deferred Taxes Liabilities | $415,000 | $0 | - | - |
| Current Liabilities | $32,328,000 | $4,454,000 | $5,621,000 | $6,829,000 |
| Current Deferred Liabilities | $341,000 | $124,000 | $151,000 | $112,000 |
| Payables And Accrued Expenses | $3,180,000 | $3,069,000 | $3,970,000 | $4,588,000 |
| Payables | $1,421,000 | $1,379,000 | $2,260,000 | $2,334,000 |
| Other Payable | $555,000 | $415,000 | $448,000 | $549,000 |
| Accounts Payable | $866,000 | $964,000 | $1,812,000 | $1,785,000 |
| Other Current Liabilities | - | - | - | $457,000 |
| Equity | ||||
| Common Stock Equity | $-6,842,000 | $96,000 | $13,355,000 | $30,039,000 |
| Total Equity Gross Minority Interest | $-865,000 | $5,415,000 | $15,300,000 | $32,186,000 |
| Stockholders Equity | $-6,842,000 | $96,000 | $13,355,000 | $30,039,000 |
| Retained Earnings | $-443,055,000 | $-420,472,000 | $-399,584,000 | $-371,263,000 |
| Other | ||||
| Ordinary Shares Number | $7,893,767 | $5,408,212 | $5,155,686 | $4,063,436 |
| Share Issued | $7,893,767 | $5,408,212 | $5,155,686 | $4,063,436 |
| Tangible Book Value | $-12,771,000 | $96,000 | $13,355,000 | $30,039,000 |
| Invested Capital | $20,447,000 | $24,123,000 | $36,885,000 | $51,717,000 |
| Working Capital | $-10,233,000 | $26,653,000 | $35,788,000 | $50,918,000 |
| Capital Lease Obligations | $6,761,000 | $5,585,000 | $6,375,000 | $7,124,000 |
| Total Capitalization | $-6,842,000 | $24,123,000 | $36,885,000 | $51,717,000 |
| Minority Interest | $5,977,000 | $5,319,000 | $1,945,000 | $2,147,000 |
| Additional Paid In Capital | $436,213,000 | $420,568,000 | $412,939,000 | $401,302,000 |
| Capital Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Employee Benefits | $703,000 | $605,000 | $598,000 | $867,000 |
| Non Current Pension And Other Postretirement Benefit Plans | $703,000 | $605,000 | $598,000 | $867,000 |
| Long Term Capital Lease Obligation | $6,102,000 | $5,026,000 | $5,748,000 | $6,505,000 |
| Current Deferred Revenue | $341,000 | $124,000 | $151,000 | $112,000 |
| Current Capital Lease Obligation | $659,000 | $559,000 | $627,000 | $619,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $859,000 | $702,000 | $873,000 | $1,053,000 |
| Current Accrued Expenses | $1,759,000 | $1,690,000 | $1,710,000 | $2,254,000 |
| Defined Pension Benefit | $610,000 | $470,000 | $439,000 | $661,000 |
| Goodwill | $3,136,000 | $0 | - | - |
| Net PPE | $8,723,000 | $7,246,000 | $8,321,000 | $9,009,000 |
| Accumulated Depreciation | $-17,986,000 | $-17,700,000 | $-17,447,000 | $-17,085,000 |
| Gross PPE | $26,709,000 | $24,946,000 | $25,768,000 | $26,094,000 |
| Leases | $9,172,000 | $8,765,000 | $8,765,000 | $8,740,000 |
| Other Properties | $15,026,000 | $13,724,000 | $14,639,000 | $15,054,000 |
| Machinery Furniture Equipment | $2,511,000 | $2,457,000 | $2,364,000 | $2,300,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $14,718,000 | $23,202,000 | $34,811,000 | $45,244,000 |
Fetched: 2026-06-18
Cash Flow Statement (Annual)
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-19,829,000 | $-18,344,000 | $-23,119,000 | $-36,781,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-18,211,000 | $-18,021,000 | $-22,857,000 | $-36,501,000 |
| Cash Flow From Continuing Operating Activities | $-18,211,000 | $-18,021,000 | $-22,857,000 | $-36,501,000 |
| Operating Gains Losses | $-556,000 | - | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-1,618,000 | $-323,000 | $-262,000 | $-280,000 |
| Investing Cash Flow | $8,026,000 | $10,584,000 | $9,698,000 | $11,783,000 |
| Cash Flow From Continuing Investing Activities | $8,026,000 | $10,584,000 | $9,698,000 | $11,783,000 |
| Net Other Investing Changes | $373,000 | - | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $9,580,000 | $91,000 | $8,024,000 | $0 |
| Financing Cash Flow | $9,533,000 | $8,841,000 | $8,024,000 | $7,500,000 |
| Cash Flow From Continuing Financing Activities | $9,533,000 | $8,841,000 | $8,024,000 | $7,500,000 |
| Net Other Financing Charges | $-47,000 | $8,750,000 | - | $7,500,000 |
| Net Common Stock Issuance | $9,580,000 | $91,000 | $8,024,000 | $0 |
| Common Stock Issuance | $9,580,000 | $91,000 | $8,024,000 | $0 |
| Other | ||||
| End Cash Position | $7,196,000 | $7,671,000 | $6,256,000 | $11,413,000 |
| Beginning Cash Position | $7,671,000 | $6,256,000 | $11,413,000 | $31,838,000 |
| Effect Of Exchange Rate Changes | $177,000 | $11,000 | $-22,000 | $-3,207,000 |
| Changes In Cash | $-652,000 | $1,404,000 | $-5,135,000 | $-17,218,000 |
| Net Investment Purchase And Sale | $9,271,000 | $10,907,000 | $9,960,000 | $12,063,000 |
| Sale Of Investment | $9,271,000 | $10,907,000 | $9,960,000 | $12,063,000 |
| Net PPE Purchase And Sale | $-1,618,000 | $-323,000 | $-262,000 | $-280,000 |
| Purchase Of PPE | $-1,618,000 | $-323,000 | $-262,000 | $-280,000 |
| Change In Working Capital | $-126,000 | $-45,000 | $-114,000 | $-2,867,000 |
| Change In Other Working Capital | $-116,000 | $574,000 | $719,000 | $2,059,000 |
| Change In Payables And Accrued Expense | $100,000 | $-1,089,000 | $-1,265,000 | $-4,690,000 |
| Change In Accrued Expense | $-42,000 | $-24,000 | $1,805,000 | $-2,222,000 |
| Change In Payable | $142,000 | $-1,065,000 | $-1,265,000 | $-4,690,000 |
| Change In Account Payable | $142,000 | $-1,065,000 | $-22,000 | $-758,000 |
| Change In Prepaid Assets | $1,000 | $-44,000 | $768,000 | $93,000 |
| Change In Receivables | $-111,000 | $514,000 | $-336,000 | $-329,000 |
| Changes In Account Receivables | $-202,000 | $76,000 | - | - |
| Other Non Cash Items | $3,262,000 | $497,000 | $1,805,000 | $-2,222,000 |
| Stock Based Compensation | $2,143,000 | $2,618,000 | $3,977,000 | $8,909,000 |
| Depreciation Amortization Depletion | $316,000 | $253,000 | $362,000 | $1,053,000 |
| Depreciation And Amortization | $316,000 | $253,000 | $362,000 | $1,053,000 |
| Depreciation | $316,000 | $253,000 | $362,000 | $1,053,000 |
| Gain Loss On Investment Securities | $-556,000 | - | - | - |
| Net Income From Continuing Operations | $-23,250,000 | $-21,344,000 | $-28,887,000 | $-41,374,000 |
| Change In Interest Payable | - | - | $1,852,000 | $-2,172,000 |
| Issuance Of Debt | - | - | - | $0 |
| Proceeds From Stock Option Exercised | - | - | - | $0 |
| Net Issuance Payments Of Debt | - | - | - | $0 |
| Net Long Term Debt Issuance | - | - | - | $0 |
| Long Term Debt Issuance | - | - | - | $0 |
| Purchase Of Investment | - | - | - | $0 |
| Pension And Employee Benefit Expense | - | - | - | - |
Fetched: 2026-06-18